MA27385A1 - Therapie combinee de maladies hyperproliferatives. - Google Patents

Therapie combinee de maladies hyperproliferatives.

Info

Publication number
MA27385A1
MA27385A1 MA28110A MA28110A MA27385A1 MA 27385 A1 MA27385 A1 MA 27385A1 MA 28110 A MA28110 A MA 28110A MA 28110 A MA28110 A MA 28110A MA 27385 A1 MA27385 A1 MA 27385A1
Authority
MA
Morocco
Prior art keywords
hyperproliferative diseases
present
treatment
relates
group
Prior art date
Application number
MA28110A
Other languages
English (en)
Inventor
Jean Saccuzzo Beebe
Karen Jean Ferrante
Jitesh Pranlal Jani
Tracey Lee Schaeffer
Diane Ingeborg Healey
James John O'leary
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27385A1 publication Critical patent/MA27385A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 19 Août 2002 60/404,461 Thérapie combinée de maladies hyperprolifératives La présente invention concerne une méthode pour le traitement de maladies hyperprolifératives. Plus particulièrement, la présente invention concerne une méthode pour le traitement de maladies hyperprolifératives, telles que le cancer, comprenant l'étape consistant à administrer à un mammifère, nécessitant un tel traitement, simultanément ou séquentiellement, (i) une quantité thérapeutiquement efficace d'un dérivé de taxane, d'un complexe de coordination de platine choisi dans le groupe consistant en carboplatine, tétraplatine et topotécan, d'un analogue de nucléoside choisi dans le groupe consistant en chlorhydrate de gemcitabine et 5-FU, d'une anthracycline, d'un inhibiteur de topoisomérase choisi dans le groupe consistant en l'étoposide, le téniposide, l'amsacrine, le topotécan et le Camptosar??, un inhibiteur d'aromatase ; et (ii) une quantité thérapeutiquement efficace d'un dérivé d'isothiazole. Les associations de la présente invention peuvent comprendre éventuellement un agent antihypertensif. La présente invention concerne également des compositions pharmaceutiques utiles dans le traitement de maladies hyperprolifératives chez un mammifère, contenant ces associations. La présente invention concerne également des kits comprenant un premier compartiment avec un composé de formule 1 et un deuxième compartiment contenant un dérivé de taxane, un complexe de coordination de platine, un analogue de nucléoside, une anthracycline, un inhibiteur de topoisomérase ou un inhibiteur d'aromatase, et un troisième compartiment contenant un agent antihypertensif.
MA28110A 2002-08-19 2005-02-18 Therapie combinee de maladies hyperproliferatives. MA27385A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40446102P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
MA27385A1 true MA27385A1 (fr) 2005-06-01

Family

ID=31946725

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28110A MA27385A1 (fr) 2002-08-19 2005-02-18 Therapie combinee de maladies hyperproliferatives.

Country Status (32)

Country Link
US (1) US20070197517A1 (fr)
EP (1) EP1545519B1 (fr)
JP (1) JP3835763B2 (fr)
KR (1) KR100668539B1 (fr)
CN (1) CN1681495B (fr)
AP (1) AP2005003232A0 (fr)
AR (1) AR040995A1 (fr)
AT (1) ATE502635T1 (fr)
AU (1) AU2003250483A1 (fr)
BR (1) BR0313593A (fr)
CA (1) CA2495962A1 (fr)
CR (1) CR7693A (fr)
DE (1) DE60336485D1 (fr)
EA (1) EA200500234A1 (fr)
EC (1) ECSP055618A (fr)
ES (1) ES2362998T3 (fr)
GE (1) GEP20074134B (fr)
GT (1) GT200300177A (fr)
HR (1) HRP20050163A2 (fr)
IL (1) IL166545A0 (fr)
IS (1) IS7670A (fr)
MA (1) MA27385A1 (fr)
MX (1) MXPA05001958A (fr)
NO (1) NO20050621L (fr)
OA (1) OA12905A (fr)
PA (1) PA8580201A1 (fr)
PE (1) PE20040993A1 (fr)
PL (1) PL375713A1 (fr)
RS (1) RS20050106A (fr)
TN (1) TNSN05051A1 (fr)
TW (1) TW200403057A (fr)
WO (1) WO2004017964A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2003101308A1 (fr) 2002-06-04 2003-12-11 Office Of Technology Licensing Stanford University Dispositif et procede d'aspiration et de recueil rapides de tissu de l'organisme d'un espace corporel ferme
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (fr) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Element penetrant peu douloureux
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
EP1680014A4 (fr) 2003-10-14 2009-01-21 Pelikan Technologies Inc Procede et appareil fournissant une interface-utilisateur variable
WO2005065414A2 (fr) 2003-12-31 2005-07-21 Pelikan Technologies, Inc. Procede et appareil permettant d'ameliorer le flux fluidique et le prelevement d'echantillons
WO2005102327A1 (fr) * 2004-04-20 2005-11-03 Pfizer Products Inc. Formes posologiques et procedes de traitement utilisant des inhibiteurs vegfr
EP1751546A2 (fr) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Hydrogel imprimable pour biocapteurs
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
WO2006135316A1 (fr) * 2005-06-13 2006-12-21 Astrazeneca Ab Nouveaux composes d'oxabispidine pour le traitement des arythmies cardiaques
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009117769A1 (fr) * 2008-03-25 2009-10-01 Newcastle Innovation Limited Inhibition de cancers à c-kit
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
CA2995033C (fr) 2010-11-12 2020-04-28 Pharma Mar, S.A. Pluritherapie avec un alcaloide antitumoral
JP2016520572A (ja) 2013-04-24 2016-07-14 ソーク インスティテュート フォー バイオロジカル スタディーズ ビタミンｄ受容体／ｓｍａｄゲノム回路は線維化反応を制御する
AU2014274864B2 (en) 2013-06-05 2018-10-18 Salk Institute For Biological Studies Vitamin D receptor agonists to treat diseases involving CXCL12 activity
WO2016172393A1 (fr) * 2015-04-22 2016-10-27 Syn-Nat Products Enterprise LLC Composition de co-cristaux et son utilisation pharmaceutique
JP6851989B2 (ja) 2015-05-18 2021-03-31 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬用共結晶及びその用途
US10980768B2 (en) 2015-06-19 2021-04-20 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
JP6929234B2 (ja) 2015-06-25 2021-09-01 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬共結晶組成物及びその用途
EP3397172B1 (fr) 2016-02-01 2025-10-01 Regenmed Systems, Inc. Canule pour rupture de tissu
WO2019023149A1 (fr) 2017-07-24 2019-01-31 Salk Institute For Biological Studies Utilisation d'antagonistes de la protéine 9 contenant un bromodomaine en association avec des agonistes du récepteur de la vitamine d dans le traitement du diabète
EP4061372A1 (fr) 2019-11-21 2022-09-28 Pharma Mar, S.A. Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
US11738021B2 (en) 2021-08-23 2023-08-29 Ckp Therapeutics, Inc. Composition and method for preventing, alleviating or treating cancer
US20230098628A1 (en) * 2021-08-23 2023-03-30 Ckp Therapeutics, Inc. Composition for preventing, alleviating or treating cancer
WO2026002126A1 (fr) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 Inhibiteur de protéine tyrosine kinase et préparation ophtalmique associée
WO2026002137A1 (fr) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 Forme cristalline de base libre d'inhibiteur de protéine tyrosine kinase

Family Cites Families (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108097A (en) 1963-10-22 Ehnojs
US3009911A (en) 1961-11-21 Derivatives of j
US437201A (en) 1890-09-30 Mechanism for testing reed-organs
US3254076A (en) 1966-05-31 Sulfamyl hydro
US2976289A (en) 1961-03-21 X-tetrahydro -
US2882271A (en) 1959-04-14 Xcixcxh
DE55956C (de) CH. GROOMBRIDGE und W. A. SOUTH in London, 40 New Bond Street Bremskurbel für Pferdebahn- und andere Wagen
US2783241A (en) 1957-02-26 S-acylimino-x-substituted-az-i
US2809194A (en) 1957-10-08 Thiadiazine type natriuretic agents
US2802005A (en) 1957-08-06 S-eluorourace
US3164588A (en) 1965-01-05 Hjnsoj
US3262852A (en) 1966-07-26 Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same
US2937169A (en) 1960-05-17 Toiutf alrtqn of h
US2661372A (en) 1953-12-01 Pharmacologically valuable stereo
SE168308C1 (fr)
US338899A (en) 1886-03-30 Sun-shield for horses
US2161938A (en) 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
DE905738C (de) 1943-06-11 1954-11-02 Diwag Chemische Fabriken Ag Verfahren zur Herstellung basischer Thymoldimethylaminoaethylaether
US2500444A (en) 1944-10-10 1950-03-14 Polaroid Corp Uramidohomomeroquinene
AT168063B (de) 1948-11-23 1951-04-10 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen asymmetrischen Substitutionsprodukten des 2,4-Diamino-1,3,5-Triazins
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
DE860217C (de) 1950-10-28 1952-12-18 Albert Ag Chem Werke Verfahren zur Herstellung von 1-Hexyl-3, 7-dimethylxanthin
GB740932A (en) 1952-08-01 1955-11-23 Rhone Poulenc Sa Improvements in or relating to phenthiazine derivatives
US2661373A (en) 1953-03-02 1953-12-01 Kulz Ida Certain amino alcohols and ketones
US2816118A (en) 1953-11-12 1957-12-10 S B Penick & Company Inc Isolation of crystalline components from visnagan
US2909194A (en) 1954-02-15 1959-10-20 Goodyear Tire & Rubber Relay valve
FR1103113A (fr) 1954-04-15 1955-10-31 Triméthylol-alcanes et leur procédé de préparation
GB769757A (en) 1954-05-13 1957-03-13 American Cyanamid Co Improvements in or relating to the manufacture of sulfonamides
US2769015A (en) 1954-10-06 1956-10-30 Lab Laroche Navarron Process of preparing 3-methyl-chromone
GB795174A (en) 1954-10-13 1958-05-21 Upjohn Co Heterocyclic sulphonamides
GB807826A (en) 1955-03-14 1959-01-21 Thomae Gmbh Dr K Derivatives of pyrimido[5,4-d] pyrimidine and production thereof
FR1165845A (fr) 1955-05-28 1958-10-29 Philips Nv Amines secondaires portant des substituants et leur préparation
GB803372A (en) 1955-11-02 1958-10-22 Recordati Lab Farmacologico S Hydroxychromone derivatives and methods of preparing the same
US3012042A (en) 1956-12-21 1961-12-05 Belge Produits Chimiques Sa Benzofurans
BE564542A (fr) 1957-02-05
GB824547A (en) 1957-05-07 1959-12-02 Recordati Lab Farmacologico S Process for preparing flavone-7-ethyl oxyacetate
US3055904A (en) 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
US2965655A (en) 1957-11-07 1960-12-20 Merck & Co Inc Process for preparing substituted 1-amino 2, 4-benzene-disulfonamides
US2965656A (en) 1957-11-07 1960-12-20 Merck & Co Inc Process for preparing substituted 1-amino-2, 4-benzene-disulfonamides
US2980699A (en) 1957-12-20 1961-04-18 S B Penick And Company Dihydropyranocoumarin derivatives and process for their production
US3440244A (en) 1958-02-17 1969-04-22 Pfizer & Co C 3,6-disubstituted-7-sulfamyl-1,2,4-benzthiazide-1,1-dioxides
FR1217929A (fr) 1958-03-03 1960-05-06 Ciba Geigy Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
CH366523A (de) 1958-04-14 1963-01-15 Eprova Ag Verfahren zur Herstellung der neuen 1,3,4,6- und 1,3,4,5-Tetranicotinoyl-fructose
SU115905A1 (ru) 1958-04-19 1958-11-30 Н.Е. Акопян Препарат ганглерон
BE578515A (fr) 1958-05-07
GB851287A (en) 1958-07-10 1960-10-12 British Drug Houses Ltd 5-chlorotoluene-2:4-disulphonamide and alkali metal salts thereof
DE1102750B (de) 1958-07-17 1961-03-23 Wuelfing J A Fa Verfahren zur Herstellung eines Salzes von Theophyllinbasen
GB856409A (en) 1958-07-26 1960-12-14 Chime Et Atomistique Improvements in and relating to a new pyridazine derivative and its process of preparation
GB862248A (en) 1958-08-04 1961-03-08 Italseber S P A Di-isopropylammonium salts of chloroacetic and chloropropionic acids
GB863474A (en) 1958-08-13 1961-03-22 Knud Abildgaard Benzothiadiazine derivatives and their preparation
US2970082A (en) 1958-10-07 1961-01-31 Walker Lab Inc Aluminum nicotinate compositions for hypercholesteremia
GB885078A (en) 1959-01-12 1961-12-20 Ciba Ltd 3:4-dihydro-1:2:4-benzothiadiazine-1:1-dioxides and process for their manufacture
ES255386A1 (es) 1959-02-04 1960-09-16 Ciba Geigy Procedimiento para preparar derivados del 3,4-dihidro-1,2,4-benzotiadiazina-1,1,-diëxido
US3058882A (en) 1959-12-28 1962-10-16 Hoechst Ag N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof
DE1102973B (de) 1960-03-25 1961-03-23 Bayer Ag Verfahren zur Herstellung von hoch gereinigten Kallikrein-Praeparaten
NL291944A (fr) 1960-05-04
DE1265758B (de) 1960-05-25 1968-04-11 Guidotti & C Spa Labor Verfahren zur Herstellung von o-(beta-Dialkylaminoaethoxy)-phenylketonen und deren Saeureadditionssalzen und quartaeren Salzen
US3081230A (en) 1960-09-08 1963-03-12 Smith Kline French Lab Diuretic and antihypertensive triaminoarylpteridines
DE1302648B (fr) 1960-09-27
SE300218B (fr) 1960-11-08 1968-04-22 Recip Ab
NL270803A (fr) 1960-11-09
US3255241A (en) 1961-01-19 1966-06-07 Merck & Co Inc (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids
US3072653A (en) 1961-03-06 1963-01-08 Warner Lamber Pharmaceutical C 5-amino derivatives of 4-thiazolidinones and process therefor
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
FR1312427A (fr) 1961-04-12 1962-12-21 Science Union Et Compagnie Soc Nouveaux dérivés de la pipérazine et leurs préparations
GB979994A (en) 1961-07-28 1965-01-06 May & Baker Ltd Isoindolinone derivatives
US3160641A (en) 1961-08-07 1964-12-08 Atlas Chem Ind Purification of isosorbide
NL281975A (fr) 1961-08-12
GB984810A (en) 1961-10-05 1965-03-03 Farmaceutici Italia Polypeptides
DE1236523C2 (de) 1962-02-15 1975-06-12 Sanol-Arzneimittel Dr. Schwarz Gmbh, 4019 Monheim Verfahren zur herstellung von basischen phenylaethern und deren salzen
US3262977A (en) 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
BE629910A (fr) 1962-03-22
US3188329A (en) 1962-04-10 1965-06-08 Colgate Palmolive Co Diuretic anils
US3228943A (en) 1962-06-11 1966-01-11 Lumilysergol derivatives
NL299931A (fr) 1962-10-30
NL300886A (fr) 1962-11-23
NL301580A (fr) 1962-12-11
NL142872C (fr) 1963-03-28
FR2790M (fr) 1963-05-24 1964-10-16 Soc Ind Fab Antibiotiques Sifa Nouveaux dérivés des thiachromanes.
GB1069343A (en) 1963-09-10 1967-05-17 Ici Ltd Propanolamine derivatives
US3238215A (en) 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
NL127996C (fr) 1963-11-19
BR6464291D0 (pt) 1963-11-26 1973-07-26 Merrell Inc Richardson Processo para preparar o novo composto quimico 1-1-di cloro-hexil-2-(2-piperidil)-etina
DE1278443C2 (de) 1963-11-30 1975-07-24 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,4-disulfonamid-1-chlorbenzolen
NL128190C (fr) 1964-02-07
FR1390056A (fr) 1964-04-21 1965-02-19 Holding Ceresia S A Procédé de préparation de nouveaux dérivés du tétrahydronaphtalène et produits conformes à ceux obtenus par le présent procédé ou procédé similaire
NL127065C (fr) 1964-04-22
NL137318C (fr) 1964-06-09
US3422107A (en) 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
NL130749C (fr) 1964-09-10
GB1078852A (en) 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
NL6514807A (fr) 1964-11-18 1966-05-20
NL128191C (fr) 1965-01-12
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
US3929836A (en) 1965-05-11 1975-12-30 Hoffmann La Roche 2-(2-Lower alkylamino-1-hydroxy-ethyl)-substituted benzofurans
FR1460571A (fr) 1965-06-10 1966-03-04 Innothera Lab Sa Composés thiényl acétiques et leur préparation
DE1270544B (de) 1965-06-19 1968-06-20 Beiersdorf Ag 4-Chlor-5-sulfamylsalicylsaeure-(2', 6'-dimethyl)-anilid und dessen Alkali- oder Ammonium-Salze sowie Verfahren zu deren Herstellung
DE1545575C2 (de) 1965-12-16 1970-09-10 Asta-Werke Ag, Chemische Fabrik, 4812 Brackwede N, N'-Bis- eckige Klammer auf 3"(3', 4', 5'-trimethoxybenzoyloxy)-propyl eckige Klammer zu -homopiperazin
US3360518A (en) 1966-01-03 1967-12-26 Wallace & Tiernan Inc Tetrahydro-halo-sulfamyl quinazolinones
CH472404A (de) 1966-03-04 1969-05-15 Sandoz Ag Verfahren zur Herstellung neuer Indolderivate
CH469002A (de) 1966-06-21 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer Indolderivate
FR5733M (fr) 1966-09-27 1968-01-22
FR6087M (fr) 1967-01-10 1968-06-04
US3541130A (en) 1967-02-06 1970-11-17 Boehringer Sohn Ingelheim 1-(cyanophenoxy)-2-hydroxy-3-tert.-butylamine propanes
GB1160925A (en) 1967-02-08 1969-08-06 Menarini Sas 2-Substituted Benzofuran Derivatives
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US3562257A (en) 1967-10-28 1971-02-09 Tanabe Seiyaku Co Benzothiazepine derivatives
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3857952A (en) 1967-12-22 1974-12-31 May & Baker Ltd Certain benzene derivatives useful in treating cardiac disorders
NL6903138A (fr) 1968-03-02 1969-09-04
GB1203691A (en) 1968-03-06 1970-09-03 Science Union & Cie New disubstituted n-amino indoline derivatives and process for preparing them
GB1218591A (en) 1968-04-03 1971-01-06 Delalande Sa Derivatives of n-(3,4,5-trimethoxy cennamoyl) piperazine and their process of preparation
US4045482A (en) 1968-11-12 1977-08-30 Yamanouchi Pharmaceutical Co. Ltd. 4-(3-Isopropylamino-2-hydroxypropoxy indene
DE1815922C3 (de) 1968-12-20 1979-04-26 Boehringer Mannheim Gmbh, 6800 Mannheim 5-Phenyltetrazol-Derivate
GB1249490A (en) 1968-12-24 1971-10-13 Leo Pharm Prod Ltd New sulphamyl-benzoic acid derivatives
FR8120M (fr) 1968-12-26 1970-08-03
US3836671A (en) 1969-02-21 1974-09-17 Ici Ltd Alkanolamine derivatives for producing beta-adrenergic blockade
GB1285038A (en) 1969-02-21 1972-08-09 Ici Ltd Alkanolamine derivatives
US3655663A (en) 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US3663570A (en) 1969-04-28 1972-05-16 Sankyo Co Coumarin derivatives
GB1262785A (en) 1969-04-29 1972-02-09 Orsymonde Improvements in or relating to phloroglucinol derivatives
CA956632A (en) 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
US4012444A (en) 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
BE757001A (fr) 1969-10-10 1971-03-16 Cerpha Derives heterocycliques d'acides phenoxy acetique et leur preparation
US4018824A (en) 1969-11-28 1977-04-19 Teikoku Hormone Mfg. Co., Ltd. 1-Aryloxy-3-aminopropane derivatives
US4038313A (en) 1970-01-08 1977-07-26 Ciba-Geigy Corporation Cycloalkylureido phenoxy propanolamines
US3935259A (en) 1970-01-08 1976-01-27 Ciba-Geigy Corporation New amines and processes for their manufacture
SE354851B (fr) 1970-02-18 1973-03-26 Haessle Ab
US3770724A (en) 1970-03-31 1973-11-06 Roussel Uclaf Process for preparing pentacyclic alkaloids
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3663597A (en) 1970-05-05 1972-05-16 American Home Prod Process for the purification of cyclandelate
FR2092133B1 (fr) 1970-05-06 1974-03-22 Orsymonde
US3669968A (en) 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
US4059622A (en) 1970-05-27 1977-11-22 Imperial Chemical Industries Limited Alkanolamine derivatives
DE2130393C3 (de) 1970-06-22 1981-02-26 E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) 6,7-Dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanole und ihre Salze mit Säuren sowie ihre Verwendung bei der Bekämpfung von Herzerkrankungen
FR2092895B1 (fr) 1970-06-29 1973-07-13 Lafon Victor
AT308089B (de) 1970-10-14 1973-06-25 Degussa Verfahren zur Herstellung von neuen Thienylalkanderivaten und ihren Salzen
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3853923A (en) 1971-05-13 1974-12-10 Kakenyaku Kako Kk 2-substituted-(2-hydroxy-3-lower alkaminopropoxy)-benzofurans
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3773939A (en) 1971-11-24 1973-11-20 Janssen Pharmaceutica Nv N-arallyl-n'-aralkyl piperazine pharmaceutical compositions
BE790165A (fr) 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer
BE795735A (fr) 1972-03-06 1973-06-18 Cerm Cent Europ Rech Mauvernay Nouvelles ethylenediamines substituees a activite cardiovasculaire
JPS5229318B2 (fr) 1972-03-30 1977-08-01
US3910924A (en) 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
ZA732937B (en) 1972-05-05 1974-03-27 Maggioni & C Spa Non mercurial diuretics
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US4167581A (en) 1972-12-15 1979-09-11 Imperial Chemical Industries Limited Alkanolamine derivatives and pharmaceutical compositions and uses thereof
US3985758A (en) 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
GB1390748A (en) 1973-04-09 1975-04-16 Continental Pharma Alkyl and cycloalkylthiophenylalkylaminoalkanols their salts and the preparation thereof
DE2319278C2 (de) 1973-04-17 1986-02-20 Bayer Ag, 5090 Leverkusen Pharmazeutisches Mittel
US4146643A (en) 1973-12-18 1979-03-27 Sandoz Ltd. Increasing vigilance or treating cerebral insufficiency with substituted vincamines
AT334385B (de) 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
NL175059C (nl) 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
GB1501632A (en) 1974-06-28 1978-02-22 Cm Ind Aromatic ketones having cardiovascular activity
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE2419970C3 (de) 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DE2521113A1 (de) 1974-05-15 1976-03-18 Maggioni & C Spa Cycloaliphatische derivate von 3.3-diphenylpropylamin
US4338322A (en) 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
US4129565A (en) 1975-07-11 1978-12-12 Nisshin Flour Milling Co., Ltd. Isocarbostyril derivatives
US4340541A (en) 1975-08-15 1982-07-20 Sandoz Ltd. 4-(2-Benzoyloxy-3-tert.-butylaminopropoxy-2-methyl indole
US4035750A (en) 1975-10-14 1977-07-12 Eastman Kodak Company Electrophotographic apparatus having improved photoconductor regenerative structure and procedure
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4154839A (en) 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US4046889A (en) 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
GB1544872A (en) 1976-06-25 1979-04-25 Sterling Drug Inc 4-hydroxyphenylalkanolamine derivatives and preparation thereof
DE2645710C2 (de) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4466972A (en) 1977-06-20 1984-08-21 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
CA1147342A (fr) 1977-10-12 1983-05-31 Kazuo Imai Procede de preparation de nouveaux derives de la phenylethanolamine
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
IT1088554B (it) 1977-11-17 1985-06-10 F I D I A Spa Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina
JPS55301A (en) 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
SE429652B (sv) 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
JPS559058A (en) 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4470972A (en) 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
JPS57209270A (en) 1981-06-19 1982-12-22 Chugai Pharmaceut Co Ltd Proline derivative
GB2111978B (en) 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
IE55867B1 (en) 1981-12-29 1991-02-14 Hoechst Ag New derivatives of bicyclic aminoacids,processes for their preparation,agents containing these compounds and their use,and new bicyclic aminoacids as intermediates and processes for their preparation
US4555502A (en) 1982-09-30 1985-11-26 Merck & Co., Inc. Aminoacyl-containing dipeptide derivatives useful as antihypertensives
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
EP0094159B1 (fr) 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dérivés de la dihydropyridine, leur préparation et leur application
JPS6058233B2 (ja) 1982-05-24 1985-12-19 田辺製薬株式会社 ２−オキソイミダゾリジン誘導体及びその製法
US4452790A (en) 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4463176A (en) 1982-09-13 1984-07-31 Mead Johnson & Company Process for resolution of optical isomers
AU557175B2 (en) 1982-10-15 1986-12-11 Kyowa Hakko Kogyo Co. Ltd. 2,6-dimethyl-4-(3-nitro phenyl)-1,4-dihydro pyridine-3,5- dicarboxylic acid esters
US4567175A (en) 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
JPS60222472A (ja) 1984-03-30 1985-11-07 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
SU1435151A3 (ru) 1984-04-10 1988-10-30 Санкио Компани Лимитед (Фирма) Способ получени производных пергидротиазепина или их кислотно-аддитивных фармацевтически приемлемых солей
US4672068A (en) 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
NZ212895A (en) 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
ATE71622T1 (de) 1985-07-29 1992-02-15 Santen Pharmaceutical Co Ltd Neue benzothiazinabkoemmlinge.
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1319144C (fr) 1986-11-14 1993-06-15 Quirico Branca Derives tetrahydronaphtalene
ATE61588T1 (de) 1987-08-03 1991-03-15 Delagrange Lab 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2356929A1 (fr) * 1998-12-23 2000-07-06 G.D. Searle & Co. Methode d'utilisation d'un inhibiteur du support de la metalloproteinase et d'un ou de plusieurs agents antineoplastiques comme therapie combinatoire pour le traitement de la neoplasie
AU2001278322B2 (en) * 2000-07-27 2005-12-22 Smith & Nephew (Overseas) Limited Treatment of hyperproliferative skin disorders and diseases
CA2430065C (fr) * 2000-11-28 2008-05-20 Pfizer Products Inc. Sels d'un isothiazole-4-carboxamide et leur utilisation comme agents anti-hyperproliferatifs

Also Published As

Publication number Publication date
EP1545519A1 (fr) 2005-06-29
GEP20074134B (en) 2007-06-25
JP2006500374A (ja) 2006-01-05
HRP20050163A2 (en) 2005-06-30
HK1079106A1 (zh) 2006-03-31
JP3835763B2 (ja) 2006-10-18
DE60336485D1 (de) 2011-05-05
AP2005003232A0 (en) 2005-03-31
AU2003250483A1 (en) 2004-03-11
KR20050058351A (ko) 2005-06-16
AR040995A1 (es) 2005-04-27
EA200500234A1 (ru) 2005-08-25
PL375713A1 (en) 2005-12-12
TW200403057A (en) 2004-03-01
MXPA05001958A (es) 2005-04-28
CA2495962A1 (fr) 2004-03-04
ECSP055618A (es) 2005-04-18
ATE502635T1 (de) 2011-04-15
CN1681495B (zh) 2010-05-12
PA8580201A1 (es) 2004-08-31
NO20050621L (no) 2005-05-18
IS7670A (is) 2005-01-27
EP1545519B1 (fr) 2011-03-23
US20070197517A1 (en) 2007-08-23
RS20050106A (sr) 2007-11-15
OA12905A (en) 2006-10-13
WO2004017964A1 (fr) 2004-03-04
GT200300177A (es) 2004-04-19
IL166545A0 (en) 2006-01-15
KR100668539B1 (ko) 2007-01-16
BR0313593A (pt) 2005-07-12
PE20040993A1 (es) 2004-12-29
CR7693A (es) 2005-06-15
CN1681495A (zh) 2005-10-12
ES2362998T3 (es) 2011-07-18
TNSN05051A1 (fr) 2007-05-14

Similar Documents

Publication Publication Date Title
MA27385A1 (fr) Therapie combinee de maladies hyperproliferatives.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu&#39;inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA27095A1 (fr) Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu&#39;agents anticancereux
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
MA24729A1 (fr) Macrolides nouveaux.
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA26960A1 (fr) Sels d&#39;un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
MA31024B1 (fr) Nouveaux derives de l&#39;isoquinoleine et de l&#39;isoquinoleinone substituees
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d&#39;une croissance cellulaire anormale
MA31022B1 (fr) Derives de l&#39;isoquinoleine et de l&#39;isoquinoleinone substituees
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MA27305A1 (fr) Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu&#39;inhibiteurs de renine dans le traitement de l&#39;hypertension, de maladies cardiovasculaires ou renales
MA29213B1 (fr) Quinolones a substitution macrolones - amino
FR2918571B1 (fr) Compositions antibiotiques a base d&#39;huiles essentielles prophylaxie et traitement d&#39;infections nosocomiales
TNSN00235A1 (fr) Derives d&#39;heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
HUP0202656A2 (hu) 1-Amino-triazolo[4,3-a]kinazolin-5-on- és/vagy -5-tion-származékok foszfodiészteráz-IV gátlására, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MA30296B1 (fr) Nouvelles amines
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA30313B1 (fr) Amines secondaires en tant qu&#39;inhibiteurs de la renine
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto